Real-world Safety Assessment of Treatment of Chronic Inflammatory Demyelinating Polyneuropathy with Subcutaneous IgPro20 (P10-11.023)
This retrospective real-world study evaluated safety outcomes in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) treated with subcutaneous IgPro20 (Immune Globulin [Human], 20% Liquid).
Authors
- Yi Wang (ORCID: https://orcid.org/0000-0002-2936-3687)
- Katharine Coyle (ORCID: https://orcid.org/0000-0003-4842-5131)
- Betsy J. Lahue (ORCID: https://orcid.org/0000-0002-8659-1336)
- Victoria Divino (ORCID: https://orcid.org/0000-0001-5555-7912)
- Rajiv Mallick (ORCID: https://orcid.org/0000-0002-0273-9680)
- Mitch DeKoven
- Alphonse P. Hubsch (ORCID: https://orcid.org/0000-0001-7139-0526)
Institutions
- IQVIA (United Kingdom) (GB)
- Alkem (India) (IN)
- CSL (Switzerland) (CH)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000211206
- Primary Topic
- Peripheral Neuropathies and Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00